SORT1 Genotype

Two people can eat the same diet, exercise the same way, and end up with very different LDL cholesterol numbers and very different heart attack risks. A meaningful chunk of that difference is written into your DNA at a single stretch of chromosome 1, and this test reads it. Knowing what you inherited at this region tells you whether your genetic background is helping or hurting your cardiovascular risk before any lifestyle work even enters the picture.

SORT1 (sortilin 1) is an intracellular sorting protein in liver cells that helps route cholesterol-carrying particles to their correct destination inside the cell, including for breakdown or for export back into the bloodstream. The version of the gene you inherit affects how much of this protein your liver makes, and that in turn affects your LDL cholesterol, your odds of coronary artery disease, and a handful of other outcomes that standard cholesterol testing alone will not catch.

What This Test Is Actually Reading

The strongest genetic signal for LDL cholesterol in the entire genome sits in a region of chromosome 1 called 1p13.3, which holds three neighboring genes: SORT1, CELSR2, and PSRC1. The variants that matter are not inside the protein-making part of these genes. They sit in nearby regulatory DNA that controls how much of each protein your liver produces, and the same variants can adjust all three genes in tissue-specific ways. SORT1 has received the most attention, but attributing the entire effect to SORT1 alone is itself a simplification.

One variant in particular, called rs12740374, creates a binding site for a protein that switches on the SORT1 gene in liver cells. People who inherit this variant make more sortilin in the liver, and exactly how that translates into lower LDL is still debated: some research suggests it pulls more LDL particles into liver cells for clearance, while other research suggests it changes how the liver packages and exports cholesterol-carrying particles. A closely linked variant, rs599839, shows the same overall pattern: each copy of the protective version is tied to lower LDL cholesterol, more sortilin gene activity, and faster LDL uptake by cells in laboratory experiments.

Heart Attack and Coronary Artery Disease Risk

This is the most established consequence of your SORT1 region genotype. The same variants that lower LDL cholesterol also lower the risk of coronary artery disease, and the variants that raise LDL raise that risk. A systematic review and meta-analysis of the CELSR2-PSRC1-SORT1 region found that carriers of certain variants showed an increased risk for cardiovascular diseases, with the strongest signal for coronary artery disease.

The effect shows up directly on the inside of arteries, not just on a lab report. In a study of 2,429 people undergoing coronary angiography, those with the higher-risk genotype at a closely linked variant called rs629301 had more extensive arterial narrowing than those with the protective version, along with higher LDL cholesterol, higher non-HDL cholesterol, and higher apoB. The investigators estimated the genotype carried roughly the same risk of significant blockage as adding ten years of age.

Abdominal Aortic Aneurysm

The same region also affects the risk of abdominal aortic aneurysm, a dangerous bulging of the body's largest artery. In a large pooled analysis of more than 7,000 cases and 75,000 controls, the protective version of rs599839 was tied to lower aneurysm risk at a genome-wide level of statistical significance, and modeling suggested the effect was independent of traditional risk factors. This is one of the more surprising findings about the SORT1 region: it is not just about cholesterol numbers, it appears to influence the structural integrity of arteries as well.

Frontotemporal Dementia

Rare coding variants directly inside the SORT1 gene, which change the structure of the sortilin protein itself, are enriched in people with frontotemporal dementia. A meta-analysis across several European cohorts (about 4,018 participants total) established SORT1 as a genetic risk factor for this form of dementia. These are different variants from the common regulatory ones that affect LDL cholesterol, and they are rare in the general population. Most genotyping panels do not look for them unless someone is being worked up for early-onset dementia or has a relevant family history.

Alzheimer's Disease

A noncoding SORT1 variant called rs17646665 was associated with reduced Alzheimer's disease risk in a Swedish cohort of 1,727 people. This is a single-cohort finding and weaker than the cardiovascular evidence. A separate study in a Chinese Han population did not find an association, which reinforces that this is preliminary. It hints that sortilin biology may be relevant to the brain as well as the liver, but it should not be the reason you order this test on its own.

Statin Response and Other Effects

Two large pharmacogenetic meta-analyses identified SORT1 region variants as factors in how much LDL cholesterol falls when people take statins, but the effects were small, on the order of a few percent of the overall drop. A separate study of roughly 13,968 adults from the ARIC cohort linked the LDL-lowering version of rs12740374 to lower levels of protein C, a clotting factor, suggesting the region also nudges the body's clotting system. None of these secondary effects are large enough to change clinical management on their own.

What the Results Look Like

A SORT1 genotype report will typically tell you which combination of letters you carry at one or more of the key variants (rs599839, rs12740374, rs646776, or a rare coding variant). You inherit one copy from each parent. So your result is one of three categories at each variant: two protective copies, one protective and one risk copy, or two risk copies. The size of the effect on LDL cholesterol or coronary disease risk roughly scales with how many copies of the risk version you carry.

Why a Standard Lipid Panel Misses This

Your LDL cholesterol number reflects the result of dozens of inputs: diet, exercise, weight, age, other genes, and your SORT1 region all rolled together. A 28-year-old with two risk copies whose LDL is currently 110 mg/dL may look identical on paper to someone with two protective copies and a poor diet whose LDL is also 110. They have very different long-term trajectories. SORT1 genotyping tells you which of those situations you are actually in, which changes how aggressively you should be working to lower LDL through other means.

Reconciling the Mixed Picture

Some research suggests that higher sortilin activity in the liver lowers LDL by directing apoB-containing particles to be broken down inside liver cells. Other research suggests sortilin can also help export cholesterol-carrying particles out of the liver, which would do the opposite. More recent work suggests the dominant direction may depend on metabolic stress conditions. The directionality has been described as still debated in expert reviews. Practically, this scientific debate does not change your genotype or its association with cardiovascular outcomes, which is consistent across large studies. It just means the precise mechanism is not fully settled.

What This Test Cannot Tell You

This is one piece of the inherited cardiovascular risk puzzle, not the whole thing. Other major genes (APOE, LDLR, PCSK9, the Lp(a) locus) also shape lifetime risk and are not covered by SORT1 genotyping. A clean SORT1 result does not mean your genetic risk is low overall. A high-risk SORT1 result does not destine you to a heart attack. The same logic applies to the dementia findings: SORT1 variants are one input among many, and most people who carry them will never develop frontotemporal dementia or Alzheimer's disease.

One-Time Result, Lifelong Implications

Your SORT1 genotype is fixed at conception and does not change. You do not need to repeat this test. The value of the result comes from how you use it over the next several decades to drive other monitoring and lifestyle decisions. If you carry the higher-risk version, you should know your ApoB and LDL particle number sooner and more often than someone without it, ideally starting in your 20s or 30s. You should also pay closer attention to other modifiable contributors to LDL cholesterol and arterial inflammation. If you carry the protective version, you can feel modestly more reassured by a borderline LDL reading, although the rest of your cardiovascular workup still matters.

What an Unfavorable Result Should Make You Do

If you carry one or two risk copies at the SORT1 region, the next step is not to retest your genotype but to deepen your lipid and cardiovascular workup. A standard cholesterol panel is the bare minimum. ApoB, Lp(a), and an advanced lipoprotein particle analysis give a sharper picture of how your inherited tendency is actually translating into circulating risk. If those numbers are also elevated, a conversation with a lipidologist or preventive cardiologist about earlier and more aggressive LDL-lowering becomes reasonable. If you carry rare coding variants associated with dementia risk, a referral to a neurologist or genetic counselor is appropriate, especially if there is a family history of frontotemporal dementia or early cognitive change.

When the Result Can Mislead You

• Variant panel coverage: the test only reports the specific variants it was designed to detect. A 'negative' or low-risk result does not rule out other rare or undiscovered variants in or near SORT1 that the assay does not check.
• Ethnic-specific allele frequencies: the protective and risk versions of these variants are common in some populations and rarer in others, and most of the large outcome studies were done in people of European ancestry. The clinical meaning of your specific result depends on your ancestry.
• Variants of uncertain meaning: a rare coding variant in SORT1 may be reported with unclear clinical significance, especially for the dementia-linked variants where the evidence is newer.
• Direct-to-consumer vs clinical-grade testing: consumer genetic services sometimes report on a single SORT1 region variant in a way that overstates or understates risk. A clinical-grade genotyping or sequencing assay reads multiple variants and reports them in a more interpretable form.